Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAZ BABER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1740365808
CMS profile
169404
Location
NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$17.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $17.48 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
LivaNova USA, Inc. $17.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAZ BABER

NPI 1740365808 · CMS profile ID 169404

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RIAZ BABER, NPI 1740365808, CMS profile ID 169404, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $17.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $17.4810/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 711985543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.48 1
PY2021 $25.10 1
PY2022 $90.37 4
PY2023 $52.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $341,122.24 185
PY2024 Principal investigator $389,598.32 164
PY2023 Recipient $20,894.00 17
PY2023 Principal investigator $262,289.24 63
PY2022 Recipient $8,539.60 3
PY2022 Principal investigator $221,491.86 60
PY2021 Recipient $40,104.00 15
PY2021 Principal investigator $235,417.23 45
PY2020 Principal investigator $547,839.81 74
PY2019 Recipient $1,141.05 5
PY2019 Principal investigator $378,637.76 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $582.00 12/31/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 789015999
Principal investigator 1 Allergan, Inc. $1,080.00 12/31/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 789016001
Principal investigator 1 Allergan, Inc. $87.00 12/31/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A 6-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CARIPRAZINE IN PEDIATRIC PARTICIPANTS (10 TO 17 YEARS OF AGE) IN THE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 789016003
Principal investigator 1 Allergan, Inc. $254.00 12/31/2021 Non-covered Recipient Entity
SOONER CLINICAL RESEARCH
A 6-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CARIPRAZINE IN PEDIATRIC PARTICIPANTS (10 TO 17 YEARS OF AGE) IN THE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 789016005
Recipient Purdue Pharma L.P. $1,882.80 12/20/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879985
Principal investigator 1 Janssen Research & Development, LLC $7,619.00 12/10/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 787611117
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,281.52 12/03/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 851030973
Recipient Purdue Pharma L.P. $470.70 12/01/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879973
Principal investigator 1 Janssen Research & Development, LLC $8,850.00 11/26/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 787611109
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $503.24 11/18/2021 Non-covered Recipient Entity
BABER RESEARCH GROUP
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851030095
Principal investigator 1 LivaNova USA, Inc. $687.15 11/18/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267313
Principal investigator 1 LivaNova USA, Inc. $496.80 11/11/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267311
Recipient Purdue Pharma L.P. $1,017.00 10/25/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879965
Principal investigator 1 LivaNova USA, Inc. $74.25 10/21/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267315
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $10,638.04 10/20/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 851028165
Principal investigator 1 Allergan, Inc. $300.00 10/14/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 789015995
Principal investigator 1 Allergan, Inc. $400.00 10/14/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 789015997
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,529.26 10/07/2021 Non-covered Recipient Entity
BABER RESEARCH GROUP
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851027971
Recipient Purdue Pharma L.P. $979.20 10/04/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879955
Principal investigator 1 LivaNova USA, Inc. $5,058.45 09/30/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267257
Principal investigator 1 LivaNova USA, Inc. $13.50 09/22/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267253
Principal investigator 1 LivaNova USA, Inc. $99.40 09/22/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267255
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $15,932.16 09/21/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 851027507
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,216.98 09/21/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 851027509
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $83.78 09/21/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 851027511
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $58.85 09/08/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 851027349
Recipient Purdue Pharma L.P. $5,937.30 09/01/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879945
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $10,000.00 08/11/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 851026749
Recipient Purdue Pharma L.P. $2,462.40 08/05/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879935
Recipient Purdue Pharma L.P. $1,017.00 07/27/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879925
Principal investigator 1 LivaNova USA, Inc. $10,103.40 07/22/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267251
Recipient Purdue Pharma L.P. $150.00 07/13/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879915
Principal investigator 1 Allergan, Inc. $53,078.90 07/08/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 789015993
Recipient Purdue Pharma L.P. $5,992.20 06/02/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879905
Principal investigator 1 H. Lundbeck A S $168.51 05/26/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 1179405664
Principal investigator 1 H. Lundbeck A S $168.51 05/26/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 853089897
Principal investigator 1 LivaNova USA, Inc. $10,000.00 05/26/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267181
Principal investigator 1 Allergan, Inc. $3,649.25 05/24/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 789015991
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,000.00 05/20/2021 Non-covered Recipient Entity
BABER RESEARCH GROUP
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032529
Principal investigator 1 Allergan, Inc. $13,942.30 05/13/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 789015989
Recipient Purdue Pharma L.P. $1,575.90 05/03/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879895
Recipient Purdue Pharma L.P. $150.00 04/26/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879885
Recipient Purdue Pharma L.P. $2,808.90 04/06/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879875
Principal investigator 1 H. Lundbeck A S $3,959.02 04/01/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 1179405528
Principal investigator 1 H. Lundbeck A S $3,959.02 04/01/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 853089681
Principal investigator 1 LivaNova USA, Inc. $195.00 04/01/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267175
Principal investigator 1 H. Lundbeck A S $3,183.12 03/18/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 853089555
Principal investigator 1 LivaNova USA, Inc. $5,044.95 03/11/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 844267087
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $8,500.00 03/04/2021 Non-covered Recipient Entity
BABER RESEARCH GROUP
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032313
Recipient Purdue Pharma L.P. $15,510.60 02/22/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879865
Recipient Purdue Pharma L.P. $75.00 02/12/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879857
Principal investigator 1 Allergan, Inc. $546.25 02/11/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 789015987
Principal investigator 1 Allergan, Inc. $2,000.00 02/09/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 789015983
Principal investigator 1 Allergan, Inc. $1,500.00 02/09/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 789015985
Principal investigator 1 H. Lundbeck A S $35.00 02/08/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 853089317
Principal investigator 1 H. Lundbeck A S $14,045.24 01/27/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 853089253
Principal investigator 1 H. Lundbeck A S $87.78 01/21/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) No dispute reported 06/30/2026 853089177
Principal investigator 1 Allergan, Inc. $16,005.60 01/18/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 789015981
Principal investigator 1 Allergan, Inc. $400.00 01/12/2021 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 789015979
Recipient Purdue Pharma L.P. $75.00 01/11/2021 Covered Recipient Physician Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844879847